Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3825323 | Progrès en Urologie | 2010 | 9 Pages |
Abstract
Cytoreductive nephrectomy is an established treatment option prior immunotherapy in well-selected patients with metastatic renal cell carcinoma. With the recent introduction of new targeted agents, the role of surgery has been source of controversy. This review examines the role of cytoreductive nephrectomy during the immunotherapy era, then in the new targeted therapies era. This review also summarizes the optimal timing of these treatments, the prognostic factors predicting outcome following cytoreductive nephrectomy, the role of metastasectomy, partial and laparoscopic cytoreductive nephrectomy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
F. Arroua, C. Maurin, A. Carcenac, E. Ragni, D. Rossi, C. Bastide,